**Supplementary Table S1.** Characteristics of 14 ovarian cancer PDX models.

| PDX ID | Subtype | Prior Chemo-therapy | Previous Platinum | PARP inhibitor Sensitivity | *BRCA* Germline | BROCA Mutations | PAX8 (IHC) | MYC (IHC Score)* | MYC Copy Number ** | CCNE1 Copy Number ** |
|---|---|---|---|---|---|---|---|---|---|---|
| | | **Clinical Attributes** | | | | **Genomic Characteristics** | | | | |
| DF20 | HGSOC | 0 | No | Resistant | Unknown | *TP53, PTEN, PPM1D* | Positive | 0 | 2.91 | 2.59 |
| DF83 | HGSOC | 4 | Yes | Sensitive | Unknown | *TP53, CDKN2A* (copy loss) | Positive | 1 | 2.12 | 2.2 |
| DF09 | HGSOC | 0 | No | Resistant | Unknown | *TP53* | Positive | 1 | 1.99 | 2.34 |
| DF14 | HGSOC | 5 | Yes | Resistant | Unknown | *TP53* | Positive | 1 | 3.01 | 2.25 |
| DF106 | HGSOC | 1 | Yes | Resistant | Unknown | *TP53, CDKN2A* (copy loss) | Positive | 1 | 3.12 | 2.17 |
| DF118 | HGSOC | 1 | Yes | Resistant | Unknown | *TP53* | Positive | 2 | 2.67 | 2.14 |
| DF149 | HGSOC | 0 | No | Resistant | Wildtype | *TP53* | Positive | 2 | 2.42 | 2.77 |
| DF172 | Mixed | 2 | Yes | Resistant | Unknown | *TP53, RET, RAD51C* | Positive | 2 | 2.42 | 5.83 |
| DF181 | HGSOC | 7 | Yes | Resistant | Wildtype | *TP53, BRIP1* | Negative | 0 | 3.2 | 2.41 |
| DF216 | Adenocarcinoma | 2 | Yes | Resistant | Wildtype | *TP53* | Positive | 2 | 3.24 | 2.47 |
| DF59 | HGSOC | 7 | Yes | Resistant | *BRCA1* 5385insC | *TP53, BRCA1, TP53BP1* | Positive | 1 | 3.35 | 2.26 |
| DF68 | HGSOC | 5 | Yes | Resistant | *BRCA1* Q563X | *TP53, BRCA1, PTEN* (copy loss) | Positive | N/A | 2.31 | 2.3 |
| DF86 | HGSOC | 6 | Yes | Resistant | *BRCA1* del exons 21-24 | *TP53, BRCA1, APC* | Positive | 2 | 4.37 | 3.66 |
| DF101 | HGSOC | 2 | Yes | Resistant | *BRCA1* 187del AG | *TP53, BRCA1, NBN, PTEN* (copy loss) | Positive | 0 | 2.44 | 2.27 |

Most of the data reported in this table are from Liu JF et al, Clinical Cancer Res 2017;23:1263-73.

*For MYC immunohistochemistry (IHC), scoring of 0 = null (no staining sample), 1 = normal (< 3+ intensity in < 50% of the cells) and 2 = amplified (strong expression (3+ intensity) in > 50% of cells)

** *MYC* and *CCNE1* copy number data are from array CGH analysis from Liu JF et al, Clinical Cancer Res 2017;23:1263-73. Note that DF172 model exhibits significant copy gain of *CCNE1*, encoding Cyclin E.

The four *BRCA1*-mutant PDX models are shaded in blue.